patients with primary acute myeloid leukaemia were treated with induction therapy consisting of daunorubicin 50 mg/m2 ( days 1 and 2 ) and continuous cytosine arabinoside 400 mg/m2 ( days 1-5 ) with a 7-10-day gap between courses .
C0023467
acute myeloid leukaemia
C0011015
daunorubicin